
CUREVAC
the RNA people®
CureVac´s COVID-19 vaccine
CVnCoV –
Product Information
The Netherlands, 11 March, 2021 – strictly confidential -

Forward Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the "company") contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potency efficacy of the company's vaccine candidate and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.


CUREVAC
the RNA people
Clinical Update

CVnCoV: clinical update

✓ Dose-range study (001/N=264) completed, reported and submitted to EMA

✓ Recruitment of dose-confirmation study (002/N=596) in young/older adults completed

✓ Recruitment of safety database completed on February 11

- As per EMA agreement: Database of 3,000 subjects exposed to CVnCoV
- 6-week safety follow up achieved by April 22nd

Good progress of pivotal study HERALD (Phase 2b/3):

- Phase 2b recruitment completed on February 11 ✓
- Phase 3 recruitment: 14,023 subjects (as of March 4th)
- Efficacy read-out (interim analysis/N=56) projected in April 2021, contingent on attack rate and on potential impact of variant strains' circulation on the number of cases required at interim.

PIP submitted, protocol amendment for inclusion of adolescents (12 to 17 years of age) in progress


Path to Marketing Authorization

CVnCoV - Progress and path towards EMA approval

✓ **Jan 2020**	**Design** of multiple vaccine candidates
✓ **Mar 2020**	Lead candidate **selection** out of several candidates
✓ **Jun 2020**	**GMP production** of lead candidate
✓ **Jun 2020**	CTA approval and **start of Phase 1** clinical trial
✓ **Aug 2020**	**CTA approval of Phase 2a** clinical trial in older adults
✓ **Oct 2020**	**Ph1 data** (safety and immunogenicity) - **final dose selection**
✓ **Nov 2020**	**CTA submission Phase 2b/3**
✓ **Dec 2020**	**Start Phase 2b/3** (Europe and Latam)
✓ **12-Feb 2021**	**Start of rolling review by EMA: 1st data package submitted**
Q2 2021	Projected **Conditional Marketing Application** (EMA) based on safety (n~3,000), immunogenicity and preliminary efficacy.
Q4 2021	Projected **Full Marketing Approval** (EMA)


CUREVAC
Product Information

Unmodified mRNA: Differentiated Mode of Action, Mimics Natural Immunity



- Optimizing untranslated regions based on potent, tissue-specific regulatory elements
- Optimizations allow for increased translation efficiency and immunogenicity
- Maximizing ribosome interaction for increased protein expression enables **low dose activity**

CVnCoV - Lipid Nanoparticle-based Delivery of mRNA Against SARS-CoV-2



mRNA encodes a pre-fusion conformation stabilized version of the full length spike (S) protein of SARS-CoV-2 virus

Formulation process



Lipid Nanoparticle Component contains proprietary amino lipid (ionizable) and PEG lipid as well as other structural lipids



CVnCoV optimized mRNA/LNP Coronavirus Vaccine

CVnCoV presentation: 20x multidose vial with dilution step



Note: Current Phase 1 storage is at -80°C; stability studies for commercial product are ongoing to support shelf-life at 2-8°C.

- Commercial presentation will require **one dilution step**, resulting in one **ready to use 20x multi-dose vial**
- **Injected volume** for 12µg dose will be **0.5ml**
- **Application syringes** and needles are **not part of** the **product**

Recommended syringes for administration (not provided with product)

Product name	Article number	Manufacturer	Comment
Flu+™ 0,25ml-1ml, 25G 0,25ml-1ml, 23G	25G: Ref 305834 23G: Ref 305832	BD	Low dead volume syringe/needle combination
Omnifix® F Solo, 1 ml	9161406V	BBraun	Use with low dead volume needle recommended
LDS Long Blue Needle 23G x 1¼"	011751	Frontier Medical Group	Tested with Omnifix® F Solo for extractable doses

- Recommended syringes above were specifically tested and validated for in-use period in the syringe, but in general all syringes with polypropylene cylinder are compatible with our CVnCoV vaccine candidate.
- In order to extract 20 doses from a single multi-dose vial, low dead-volume syringes and/or needles should be used.*
- The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microlitres.*
- Upon request and with sufficient planning, Curevac can support Member States in procuring Flu+ syringes from the strategic stock it has assembled.

***Final SmPC wording subject to approval by EMA**

Options are currently being evaluated to assure efficient and consistent shipping of vaccine concentrate, diluent, syringes and other supporting materials

Product components to be included in each shipment:



Option 1	Option 2
Temperature conditions: • Concentrate: 2-8°C • Diluent: **2-8°C** • Supporting components: n/a **Grouping** of concentrate, diluent, syringes and supporting components **per pallet**	Temperature conditions: • Concentrate: 2-8°C • Diluent: **2-8°C** • Supporting components: n/a **Grouping** of concentrate, diluent, syringes **in an additional outer box**






CUREVAC
CMO Network, Manufacturing & Stability

CVnCov stability profile expected to allow a standard 2-8°C cold chain distribution

2-8°C shelf life of 3+ months

For 24 hours[1]



Storage at CureVac	International delivery	Storage in-country	Distribution to vaccination centers	Individual vaccinations
-80°C	**2-8°C**	**2-8°C**	**2-8°C**	**2-8°C or room temp.**

Facilitated logistics for decentralized storage and large-scale vaccination efforts

Expected positive impact on distribution, cost & waste compared to ultra-low cold chain requirements

1. Indicative and ICH stability studies for CVnCoV are ongoing and results may change; transport stability at 4°C tested over 36h transport in trucks

CureVac is ramping-up an EU-based network for manufacturing, filling, packaging and shipping of CVnCoV

Current partner network in EU

pDNA production	1
mRNA production mRNA / LNP formulation	6
Filling	2
Labelling/packaging/ shipping	2
Diluent production	3

Manufacturing ramp-up of CVnCoV delayed by 3 months – deliveries will meet EU APA supply commitments by Q4 2021

CUREVAC

CURRENT FORECAST SUPPLY



Maximum shipped
Minimum shipped
EU APA

- One quarter late at start. **Significant ramp up** of production to reach the **ordered quarterly doses in Q4/2021**
- Substantial number of **formulated mRNA and filled vials will be in inventory awaiting release** and regulatory approval of suppliers
- **Pending resolution of supplier issues** including those linked to the **US Defense Production Act**
- **The Netherlands will receive 4.77% of all EU APA volumes**
- **Outstanding doses from Q1/Q2 will be delivered in Q4 in addition to the ordered doses in this quarter**


CUREVAC
the RNA people®
Thank you for your attention
CureVac
www.curevac.com